Notch signaling is a highly evolution arily conserved pathway implicated in diverse functions during embryogene sis and in selfrenewing tissues of the adult organism. These functions include the maintenance of stem cells, cell fate specification, proliferation, and apop tosis (ArtavanisTsakonas, 1988; Leong and Karsan, 2006) . In mammals, there are four Notch receptors (Notch14), three Deltalike ligands (Dll1, Dll3, and Dll4), and two ligands of the Jagged fam ily (Jag1 and Jag2). When membrane bound receptors interact with cognate ligands on an adjacent cell, two con secutive proteolytic cleavages of the receptor are initiated, freeing the intra cellular portion of Notch to enter the nucleus and activate the transcrip tion of target genes. The first cleavage (S2) in the heterodimerization domain (HD) by ADAM10 (A disintegrin and metalloprotease 10) generates the sub strate for the second cleavage (S3) by the secretase complex. Canonical Notch signaling requires the forma tion of a complex with a transcription factor of the CSL (CBF1/Su(H)/Lag1) family, CBF1/RBPJk/KBF2 in mam mals. CBF1 binds DNA in a sequence specific manner and acts as a repressor of transcription in the absence of Notch signaling. Displacement of corepressors bound to CBF1 by intracellular Notch (ICN) allows the recruitment of co activators, such as MamL1 (Mastermind Like1), and histone acetyltransferases, such as p300, to create a shortlived tran scriptional activation complex. Recent genomewide chromatin immunopre cipitation arrays and sequencing have identified a large number of genes that can be regulated directly by Notch (Palomero et al., 2006; Hamidi et al., 2011) . Many of these target genes may be cell type specific, but there are a few well characterized transcriptional tar gets of ICNCBF1, including the HES (hairy enhancer of split) family of tran scription factors, Notchrelated ankryin repeat protein (NRARP), c-MYC, and DTX1 (Deltex1; Weng et al., 2006) .
Notch as an oncogene
The first evidence for the involvement of Notch signaling in cancer came from TALL. TALL is a neoplastic disorder accounting for 10-20% of all acute lymphoblastic leukemias. In 1991, Ellisen et al. (1991) identified a t(7;9)(q34;q34.4) translocation in TALL patients, which resulted in fusion of the 3 region of NOTCH1 into the TCR locus and consequent overexpression of the ac tive form of Notch1 (ICN1). This trans location appeared to be rare, found in <1% of TALL cases. However, 13 yr later, Weng et al. (2004) identified ac tivating NOTCH1 mutations in 56% of TALL cases examined, introducing NOTCH1 mutation as the main onco genic lesion in TALL. Two major hot spots of mutations were characterized: mutations in the HD domain that induce ligandindependent activation, and mu tations in the PEST (prolineglutamate serinethreoninerich) carboxyterminal domain that increase stability of ICN1 (Thompson et al., 2007) . Additionally, inactivating mutations were identified in FBW7, an E3 ubiquitin ligase responsi ble for ICN1 degradation and subse quent termination of Notch signaling (Malyukova et al., 2007; Maser et al., 2007; O'Neil et al., 2007; Thompson et al., 2007) . Of note, animal modeling suggested that NOTCH1 mutations (HD or PEST) are either insufficient to induce disease or are very weak onco genes in TALL, even when they are overexpressed (Chiang et al., 2008) . We recently generated knockin mice carry ing human NOTCH1 mutant alleles, and our studies also indicated that none of these mutations are sufficient to in duce disease (unpublished data).
After the discovery of its involve ment in TALL, Notch signaling was also implicated in various solid tumors, including breast cancer, medulloblas toma, colorectal cancer, non-small cell lung carcinoma (NSCLC), and melanoma Using whole transcriptome profil ing and gene set enrichment analysis, Viatour et al. (2011) showed that the Notch pathway was also upregulated in TKO mice, suggesting an oncogenic role for Notch signaling in HCC de velopment. Unexpectedly, inhibition of Notch signaling in TKO mice using DAPT, a potent secretase inhibitor, led to accelerated HCC development. And enforced activation of Notch sig naling using ICN1 led to cell cycle ar rest and apoptosis in primary HCC cells isolated from TKO mice, as well as in human HCC cell lines. To further ad dress the clinical relevance of these ob servations, the authors looked at Notch activation status in a cohort of patients. They found that patients with better survival showed significantly higher ex pression of Notchrelated genes, includ ing HES1. Taken together, these data strongly support a potential tumor sup pressor role for Notch signaling in HCC.
Our laboratory has recently found that conditional Notch lossoffunction through the deletion of Nicastrin (NCSTN), an essential component of the secretase complex, or compound deletion of NOTCH1 and NOTCH2, resulted in a myeloproliferative syn drome with common features of the human disease chronic myelomono cytic leukemia (CMML; Klinakis et al., 2011) . Whole transcriptome analysis revealed that Notch signaling inhibited a monocytic/granulocytic differentiation program in an early multipotential pro genitor. This was at least partially medi ated by direct repression of the PU.1 and C/EBP promoters by HES1. Sequenc ing of Notch pathway genes revealed that 12% of CMML patients har bored inactivating mutations in NCSTN, MAML1), APH1A, or NOTCH2. These mutations were unique to CMML and were not found in other myeloprolif erative disorders such as Polycythemia vera and myelofibrosis. Analogous to the same pathway may have growth suppressive functions in other hematopoi etic cells, skin, and pancreatic epithelium, as well as in hepatocytes.
In the skin, Notch receptor and ligand expression was found largely in the suprabasal cells, and in vitro data suggested that Notch activation induces differentiation and cell cycle arrest (Lowell et al., 2000; Rangarajan et al., 2001; Nguyen et al., 2006) . Condi tional deletion of NOTCH1 in the skin resulted in a significant increase of the basal epidermal layer (Rangarajan et al., 2001) . Consistent with a tumor suppressive function for Notch in the skin, NOTCH1 loss of function re sulted in spontaneous basal cell carcino mas that appeared in older mice and sensitization to chemically induced skin carcinogenesis (Nicolas et al., 2003) . This work also suggested that Notch acts as a tumor suppressor in the skin through suppression of the Wnt and Sonic-hedgehog pathways. A subsequent study indicated that the tumorigenic ef fect of Notch1 deletion is the result of a non-cell autonomous defect in the integrity of the skin barrier (Demehri and Kopan, 2009 ). Thus, mechanistically, tumor inhibition in the skin may involve feedback with the microenvironment in addition to cross talk between Notch and other signaling pathways.
In this issue of the Journal of Experimental Medicine, Viatour et al. (2011) propose a novel tumor suppressor role for Notch signaling in hepatocellular carcinoma (HCC). HCC is one of the most devastating cancers, with >600,000 deaths/yr worldwide, and is strongly associated with prior hepatitis virus B or C infection. To gain further insights into the mechanism driving initiation and progression of HCC, the authors generated a mouse model of the disease by deleting the retinoblastoma protein (RB) and its two related family mem bers p107 and p130 in mouse liver. These triple KO (TKO) mice devel oped liver cancer with histological and molecular features typical of human HCC. In their model, inactivation of the RB pathway led to the expansion of the stem/progenitor compartment in the liver. The authors propose that these (Ranganathan et al., 2011) . The onco genic potential of Notch activation in solid tumors was first observed in mouse mammary tumor virus (MMTV)-driven breast cancer. The integration of MMTV in specific loci of the host genome resulted in dysregulated ex pression of adjacent genes and subse quent outgrowth of tumorigenic clones. Characterization of one of these loci revealed expression of a truncated con stitutively active form of Notch4 (Gallahan et al., 1987) . In mouse models, Notch activation can clearly drive mammary tumors, and in human breast cancer, increased expression of Notch or Jag1 correlates with poor prognosis (Reedijk et al., 2005) . However, few activating mutations of the Notch pathway have been found in solid tumor patients, with most being observed in NSCLC (Westhoff et al., 2009) .
Two recent studies have identi fied activating NOTCH1 mutations in chronic lymphocytic leukemia (CLL), a frequent adult leukemia (Fabbri et al., 2011; Puente et al., 2011) . CLL is char acterized by variable clinical presenta tion and progression but can be divided into two major subtypes: one with mu tated immunoglobulin genes (IGV(H)), and another more aggressive form with nonmutated IGV(H) . Both studies iden tified NOTCH1activating mutations (mainly a frame shift mutation at codon 2515) predicted to impair Fbw7induced Notch1 degradation. Although the overall frequency was not dramatic (from 8.3 to 12.2%), these NOTCH1 mutations were primarily found in pa tients with the more clinically aggres sive nonmutated IGV(H) subtype of CLL (20.4%) in Richter syndrome (31.0%), and in chemorefractory CLL (20.8%). These results suggest that although NOTCH1 mutations are not patho gnomonic or causative of CLL, they are associated with poor prognosis and could define a distinct clinical subtype for ther apeutic intervention.
Notch as a tumor suppressor
Although Notch activation (especially at higher levels as conferred by ICN1 expression) can be oncogenic, there is growing evidence that components of embryonic development and in adult tis sues, it is perhaps not surprising that aberrant Notch signaling can result in a wide range of pathological consequences. The oncogenic function of Notch in lymphocytes and mammary tissue, versus the growthsuppressive role in HCC, CMML, HNSCC, and skin, highlights the intriguing dual role of a single sig naling pathway (see Table I for a listing of Notch function in selected cancer types). Indeed, depending on the cel lular context, Notch may promote stem cell maintenance or induce terminal differentiation.
The detailed mechanistic expla nation of this duality of action remains under investigation. We propose that in both cases (oncogenic and tumor suppressive function), Notch signaling mainly targets programs of stem and pro genitor cell differentiation, acting as a cell fate determinant. By affecting nor mal differentiation, Notch could set the stage for additional mutations and even tual cell transformation. For example, in myeloid leukemia, defective Notch sig naling (caused either by mutations or by domain of the Notch receptors and therefore predicted to be lossoffunction mutations. The significance of these mutations in HNSCC requires further validation; nevertheless, they impli cate NOTCH1 as a tumor suppressor in HNSCC.
Finally, in B cell malignancies, Notch was also reported to suppress growth and induce apoptosis, providing additional evidence that Notch could act as a tumor suppressor in hematopoietic cells (ZweidlerMcKay et al., 2005) . Another recent study suggested a similar tumor suppressor role for Notch signaling in neuroblastoma (Zage et al., 2011) . How ever these data were mostly generated from in vitro studies using enforced overexpression of ICN1 or stimulation with recombinant Notch ligand and will require further in vivo validation. It will thus be important to test the role of Notch in these disease models using in vivo genetic approaches.
Conclusion/future directions
Given that Notch is involved in an array of fundamental processes both during the tumorsuppressive function of Notch in epithelial cells and HCC, these stud ies suggested that Notch signaling may also act to prevent uncontrolled prolif eration and transformation of myeloid cells during hematopoietic development.
Furthermore, two recent studies of head and neck squamous cell carcinoma (HNSCC), the sixth most common cancer worldwide, identified mutations affecting Notch receptors. Agrawal et al. (2011) identified 28 different NOTCH1 mutations in 21/120 patients (17.5%). 11 of these mutations were nonsense or insertion/deletions predicted to result in loss of function, supporting a tumor suppressive function for Notch in HNSCC. The remaining 17 were mis sense mutations, mostly within the extra cellular EGFlike repeats that are required for receptor-ligand interaction. A study by Stransky et al. (2011) identified NOTCH1 mutations in 11% of patients analyzed and NOTCH2 or NOTCH3 mutations in an additional 11% of pa tients. Mutations identified in this study were nonsense, missense, or insertion/ deletions targeting the extracellular (Real et al., 2009) . Whereas inhibition of Notch may have clinical efficacy where Notch has an oncogenic role, activation of Notch using peptides or antibodies should be evaluated as a therapeutic target in malignancies where NOTCH plays a tumorsuppressive role.
